ArticleBMJ open2022

Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer.

Shintaro Nakano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.